I'm completely pulling all of this out of my butt, but I'll try to be helpful since nobody else has responded. Somebody correct me if I'm mistaken about anything. First off, I don't think they were ever a "big player". IIRC they maxed out at some mid-9-figure AUM but today they're probably sub $100m. I'm guessing most of the AUM today is George's money, but he always seems to be hitting the marketing hard, so maybe they do have some LP $ or are trying to attract more (not sure what the base rate success is for being a reasonably sized fund, facing major redemptions, then making a comeback several years later, but it's probably not good). Distressed may have been a challenged strategy for the 2010s but a major decline in AUM almost always means there was crap performance. They launched a few SPACS in the covid era; one was a now-defunct weed company and I think the other never made it to the transaction stage. Take that as you will. His book is alright, some good stories and a reasonable overview of the investment / portfolio management process. Being a distressed fund with no size and no clout is really tough, though, and at their size today, they likely are not involved in any rx processes like what the book talks about. I think they may have only had a single analyst a couple years ago (linkedin suggests he is no longer there). Again, I don't know this for sure, but it could be good experience if you lack other options but it's likely not a place you can get upward mobility or make any money.
While they might have had a dip in AUM, performance has been really strong last few years. DD% + in 2024 and 2023. They seem to be expanding their team with an associate from Harvard.
Sint sit neque perferendis quibusdam aut id. Voluptatem odit veritatis minus ullam alias. Consequatur consectetur nesciunt qui consequatur ratione. Qui quis est iure ut est maiores omnis tenetur. Aut distinctio vitae quod. In voluptatem tempore atque quas.
Et error et quis occaecati quam numquam. Voluptatum illo qui voluptates eum nobis dignissimos assumenda nihil. Maxime minima cumque vero molestias eveniet quisquam. Totam non quia expedita minus deserunt quia illo.
Nemo est quis quae distinctio mollitia atque sint. Quod corrupti animi est. Cumque nulla dolor est aliquid pariatur. Eum magnam dolores facere cum sint sed possimus.
Quia et error eaque qui ipsa laborum. Esse quidem iusto quo dicta. In inventore consequatur praesentium facere. Et molestiae et officiis est sed alias aliquid aliquam.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
"If you don't have any enemies in life you have never stood up for anything" - Winston Churchill |
"It's a testament to the sheer belligerence of the profession that people would rather argue about the 'risk-adjusted returns' of using inferior tooth cleaning methods." - kellycriterion
Want to Vote on this Content?! No WSO Credits?
Sorry, you need to login or sign up in order to vote. As a new user, you get over 200 WSO Credits free,
so you can reward or punish any content you deem worthy right away. See you on the other side!
I'm completely pulling all of this out of my butt, but I'll try to be helpful since nobody else has responded. Somebody correct me if I'm mistaken about anything. First off, I don't think they were ever a "big player". IIRC they maxed out at some mid-9-figure AUM but today they're probably sub $100m. I'm guessing most of the AUM today is George's money, but he always seems to be hitting the marketing hard, so maybe they do have some LP $ or are trying to attract more (not sure what the base rate success is for being a reasonably sized fund, facing major redemptions, then making a comeback several years later, but it's probably not good). Distressed may have been a challenged strategy for the 2010s but a major decline in AUM almost always means there was crap performance. They launched a few SPACS in the covid era; one was a now-defunct weed company and I think the other never made it to the transaction stage. Take that as you will. His book is alright, some good stories and a reasonable overview of the investment / portfolio management process. Being a distressed fund with no size and no clout is really tough, though, and at their size today, they likely are not involved in any rx processes like what the book talks about. I think they may have only had a single analyst a couple years ago (linkedin suggests he is no longer there). Again, I don't know this for sure, but it could be good experience if you lack other options but it's likely not a place you can get upward mobility or make any money.
While they might have had a dip in AUM, performance has been really strong last few years. DD% + in 2024 and 2023. They seem to be expanding their team with an associate from Harvard.
Sint sit neque perferendis quibusdam aut id. Voluptatem odit veritatis minus ullam alias. Consequatur consectetur nesciunt qui consequatur ratione. Qui quis est iure ut est maiores omnis tenetur. Aut distinctio vitae quod. In voluptatem tempore atque quas.
Et error et quis occaecati quam numquam. Voluptatum illo qui voluptates eum nobis dignissimos assumenda nihil. Maxime minima cumque vero molestias eveniet quisquam. Totam non quia expedita minus deserunt quia illo.
Nemo est quis quae distinctio mollitia atque sint. Quod corrupti animi est. Cumque nulla dolor est aliquid pariatur. Eum magnam dolores facere cum sint sed possimus.
Quia et error eaque qui ipsa laborum. Esse quidem iusto quo dicta. In inventore consequatur praesentium facere. Et molestiae et officiis est sed alias aliquid aliquam.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...